Every 10-Q that Aldeyra Therapeutics Inc (ALDX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ALDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALDX filings page.
Aldeyra Therapeutics reported Q3 2025 results with a net loss of $7,688,341, reflecting lower operating expenses year over year. Research and development expense was $5,430,757 (down from $12,441,509), and general and administrative expense was $2,570,375 (down from $3,696,067). Total other income, net, was $312,791, driven by interest income of $788,694 and interest expense of $475,903.
Liquidity and balance sheet: Cash and cash equivalents were $59,340,599 and marketable securities were $15,956,740 as of September 30, 2025. Total assets were $77,801,012 and stockholders’ equity was $49,244,543. Current portion of debt was $15,199,265, with the Hercules facility maturing on April 1, 2026 and interest‑only payments through that date under the amendment. The company stated its cash, cash equivalents, and marketable securities are expected to fund operations for at least the next 12 months.
Strategic items: Deferred collaboration revenue remained $6,000,000 related to the AbbVie option; as of November 5, 2025, AbbVie had not exercised the option. Under its $75.0 million at‑the‑market program, no shares were sold as of quarter end.
Aldeyra Therapeutics (ALDX) Q2-25 10-Q shows the clinical-stage biotech remains pre-revenue but reduced operating losses.
- Net loss narrowed to $9.8 m (-42% YoY) on R&D cut to $8.5 m (-43%) and G&A cut to $1.7 m (-45%). Six-month loss fell to $19.7 m (-21%).
- Cash resources: $41.2 m cash & cash equivalents plus $40.7 m marketable securities = $81.9 m, funding “at least the next 12 months.” Cash burn H1-25 was $21.0 m vs $23.2 m prior year.
- Balance sheet shifts: Current liabilities rose to $29.5 m driven by term-loan re-classification (current portion $15.1 m) after interest-only period was extended to Apr-26; long-term debt now zero.
- AbbVie option: $6 m non-refundable fees remain deferred; AbbVie has not exercised the option to co-develop reproxalap and window now only 10 business days post-FDA decision.
- No commercial revenue; accumulated deficit reached $469.8 m.
Management believes existing liquidity plus interest income ($1.9 m YTD) cover operations for 12 months but acknowledges need for additional financing to advance late-stage assets reproxalap (dry eye) and ADX-2191 (retinitis pigmentosa) and to repay the $15.3 m Hercules facility at maturity in 2026.